101 completed, 30 unknown, 6 recruiting, 4 not yet recruiting. 72 Phase 1, 25 Phase 4, 22 Phase 3, 16 Phase 2, 5 Not applicable.
Follow Dong-A ST Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of DA-9701 in Patients With Functional Dyspepsia DA-9701, DA-9701-R, DA-9701 Placebo - Functional Dyspepsia | Phase 4 | Recruiting | Dong-A ST Co., Ltd. | 300 | 2026-08-06 | 2026-08-10 |
| A Study to Exploratively Evaluate the Safety, Tolerability and Pharmacokinetics of DA-5223 Compared With DA-5223-R in Healthy Adult Subjects DA-5223-R, DA-5223-F, DA-5223-M - Healthy Adult | Phase 1 | Completed | Dong-A ST Co., Ltd. | 12 | 2026-06-15 | 2026-07-15 |
| A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma DA-3501 - Gastric (Stomach) Cancer, GastroEsophageal Cancer | Phase 1 | Recruiting | Dong-A ST Co., Ltd. | 51 | 2026-05-18 | 2026-05-20 |
| A Study to Evaluate the Bioequivalence of DA-5230 Compared to DA-5230-R DA-5230, DA-5230-R - Healthy Adult Participants | Phase 1 | Completed | Dong-A ST Co., Ltd. | 62 | 2026-05-04 | 2026-10-07 |
| Pharmacokinetics and Safety Profiles of DA-1229_01 in Healthy Subjects at Fed State DA-1229_01, DA-1229_01-R - Healthy | Phase 1 | Completed | Dong-A ST Co., Ltd. | 36 | 2026-01-06 | 2026-04-07 |
| Pharmacokinetics and Safety Profiles of DA-1229_01 in Healthy Subjects at Fasting State DA-1229_01, DA-1229_01-R - Healthy | Phase 1 | Completed | Dong-A ST Co., Ltd. | 42 | 2025-12-14 | 2026-03-31 |
| Clinical Trial of Comparing DA-2902 and DA-2902-R in Healthy Adult Subjects DA-2902, DA-2902-R - Infective Disorder | Phase 1 | Completed | Dong-A ST Co., Ltd. | 40 | 2025-11-07 | 2026-06-02 |
| Clinical Trial to Evaluate the Efficacy and Safety of DA-5218 in Patients With Type 2 Diabetes DA-5218, DA-5218-C - Diabete Mellitus | Phase 4 | Not yet recruiting | Dong-A ST Co., Ltd. | 238 | 2025-11-01 | 2025-11-17 |
| Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control DA-2811, DA-2811-C - Diabete Mellitus | Phase 2 | Not yet recruiting | Dong-A ST Co., Ltd. | 288 | 2025-11-01 | 2025-11-20 |
| A Study to Evaluate the Food Effect on the Pharmacokinetics of DA-5223 in Healthy Adult Subjects DA-5223(Fasting), DA-5223(Fed) - Healthy Adult | Phase 1 | Withdrawn | Dong-A ST Co., Ltd. | 2025-11-01 | 2026-06-03 | |
| A Study to Evaluate the Pharmacokinetics and Safety of Diluted vs. Undiluted Intravenous DA-5217 in Healthy Adult Subjects Diluted Intravenous DA-5217, Undiluted Intravenous DA-5217 - Healthy Adults | Phase 1 | Completed | Dong-A ST Co., Ltd. | 32 | 2025-07-16 | 2025-08-22 |
| The Effect of Two Prokinetics in Patients With Functional Dyspepsia Mosapride citrate 5 mg + DA-9701 30 mg, Mosapride citrate 5 mg + DA-9701 30 mg placebo - Functional Dyspepsia | Not applicable | Active not recruiting | Eunpyeong St. Mary's Hospital | 92 | 2025-07-08 | 2025-08-05 |
| Clinical Trial Comparing Single-administration of DA-5222 and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult Subjects in Fed State DA-5222, DA-5222-R1, DA-5222-R2 - Healthy | Phase 1 | Completed | Dong-A ST Co., Ltd. | 40 | 2025-07-07 | 2025-11-17 |
| A Study to Compare and Evaluate the Safety, Tolerability and Pharmacokinetics Between DA-5223 and DA-5223-R in Healthy Adult Subjects DA-5223-R, DA-5223 - Healthy Adult | Phase 1 | Completed | Dong-A ST Co., Ltd. | 38 | 2025-07-04 | 2025-08-19 |
| Clinical Trial of Comparing DA-5222 Single-administration and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult Subjects DA-5222, DA-5222-R1, DA-5222-R2 - Healthy | Phase 1 | Not yet recruiting | Dong-A ST Co., Ltd. | 48 | 2025-06-01 | 2025-06-06 |
| To Evaluate Effect of Food of DA-5222 in Healthy Adult Subjects DA-5222 - Healthy | Phase 1 | Not yet recruiting | Dong-A ST Co., Ltd. | 32 | 2025-05-21 | 2025-05-28 |
| A Registry-based Randomized Controlled Trial in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH) Dual-combination therapy, Triple-combination therapy, Dexcom G7, Pasta - Type 2 Diabetes | Not applicable | Recruiting | Kyu Chang Won | 5950 | 2024-11-21 | 2025-04-24 |
| Pharmacokinetics and Safety Profiles After Administration of DA-5221_01 and Co-administration of 5221_01-R1 and DA-5221_01-R2 in Healthy Adult Volunteers DA-5221_01, DA-5221_01-R1 + DA-5221_01-R2 - Healthy | Phase 1 | Unknown | Dong-A ST Co., Ltd. | 44 | 2024-09-30 | 2024-09-27 |
| Perioperative Polmacoxib Reduce Opioid Consumption for Post Operative Pain After Rotator Cuff Tear. Experimental(Acelex cap m2mg), Active Comparator(NSAIDs-excluded non-opioid or opioid analgesics) - Rotator Cuff Tear | Not applicable | Unknown | Eulji University Hospital | 150 | 2024-08-23 | 2024-09-19 |
| The Effectiveness and Safety of Dong-A Opalmon® Tablet in Patients With Acquired Lumbar Spinal Stenosis Lumbar Spinal Stenosis | Completed | Dong-A ST Co., Ltd. | 107 | 2024-08-16 | 2026-02-27 |
Showing 20 of 145. Sign in to see all of them.
Diabetes Mellitus, Type 2 (14) · Diabetes Mellitus (6) · Hepatitis B (3) · Urinary Bladder, Overactive (3) · Alopecia (2) · Arthritis, Rheumatoid (2) · Atherosclerosis (2) · Breast Neoplasms (2) · Coronary Artery Disease (2) · Diabetic Neuropathies (2) · Dry Eye Syndromes (2) · Hepatitis B, Chronic (2) · Hypertension (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Pulmonary Arterial Hypertension (2)
4-(3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl)piperazin-2-one (18) · DA-8010 (7) · dapagliflozin (6) · DA 9601 (5) · Lead (4) · Metformin (4) · naftopidil (4) · pegylated granulocyte colony-stimulating factor, human (4) · udenafil (4) · Donepezil (3) · Filgrastim (3) · DA-1241 (2) · DA-5204 (2) · DA-9701 (2) · DA-9801 (2)
South Korea (126) · United States (6) · Indonesia (1) · Netherlands (1) · Turkey (Türkiye) (1) · United Kingdom (1)
SeungHyun Kang, Ph.D (3) · Yong Chan Lee, M.D., Ph.D. (3) · Byung Kyu Suh, M.D., Ph.D. (2) · Chang Jong Kim, M.D., Ph.D. (2) · Chang Wook Jeong, M.D., Ph.D. (2) · Cheol Woo Ko, M.D., Ph.D. (2) · Choong Ho Shin, M.D., Ph.D. (2) · Dae Hwan Kang, M.D., Ph.D. (2) · Geun Am Song, M.D., Ph.D. (2) · Han Wook Yoo, M.D., Ph.D. (2) · Heon Suk Han, M.D., Ph.D. (2) · Ho Seong Kim, M.D., Ph.D. (2) · JaeHong Seo, M.D. (2) · Jin Soon Hwang, M.D., Ph.D. (2) · Kee Hyoung Lee, M.D., Ph.D. (2)
PMID 37559343, PMID 23209191, PMID 24078278, PMID 28012485, PMID 28865799, PMID 28960033, PMID 29030421, PMID 29100193, PMID 29886724, PMID 30558400, PMID 30794833, PMID 30808080, PMID 31202506, PMID 31334795, PMID 31407230, PMID 32023608, PMID 32027799, PMID 32912058, PMID 33502058, PMID 34397702, PMID 34605552, PMID 34780772, PMID 34893062, PMID 35315603, PMID 37750183, PMID 39223856, PMID 39260927, PMID 42383539, PMID 42857284